Pharmacy News

Spain’s PharmaMar says Covid-19 treatment drug shows clinical efficacy in trials, Health News, ET HealthWorld

Spain’s PharmaMar said on Wednesday the first trials of its Aplidin drug on hospitalised patients with moderate Covid-19 showed clinical effects and met safety standards.

The results of these first tests allowed the company to secure Spanish regulatory approval to carry out a late-stage trial on patients in a Phase III trial last month.

“The company has decided to share this data, which demonstrates the therapeutic potential of this drug, with the entire scientific and medical communities, along with patients,” PharmaMar said in a statement.

Britain’s medical regulator authorised the trials two months ago after the journal Science published a paper showing the drug had encouraging antiviral results during vitro testing.

Aplidin is a drug developed by PharmaMar originally to treat cancer but has an effect as an antiviral.

Shares of PharmaMar were up 1% to 80.70 euros ($98.75) in early trading.

Follow and connect with us on , Facebook, Linkedin

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.